Efficacy and safety of cytokines versus first-line sunitinib and second-line axitinib for patients with metastatic renal cell carcinoma (ESCAPE study): A study protocol for phase III randomized sequential open-label study

Yoshifumi Kadono, Hiroyuki Konaka, Kouji Izumi, Satoshi Anai, Kiyohide Fujimoto, Kei Ishibashi, Noriyasu Kawai, Taku Kato, Akinori Iba, Naoya Masumori, Kenichi Yoshimura, Atsushiu Mizokami

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Efficacy and safety of cytokines versus first-line sunitinib and second-line axitinib for patients with metastatic renal cell carcinoma (ESCAPE study): A study protocol for phase III randomized sequential open-label study'. Together they form a unique fingerprint.

Medicine & Life Sciences